FRM
CVAC

Fox Run Management’s CureVac CVAC Stock Holding History

Fox Run Management’s Portfolio CVAC Stock Details CVAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-14,457
Closed -$151K – 754
2023
Q2 		$151K Sell
14,457
-16,821
-54% -$150K 0.04% 614
2023
Q1 		$218K Buy
+31,278
New +$273K 0.07% 509
2022
Q4 		– Sell
-31,522
Closed -$248K – 673
2022
Q3 		$248K Buy
+31,522
New +$368K 0.1% 415

Other funds holding CVAC

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Fox Run Management's CVAC Position: Q3 2023 in Review

Fox Run Management sold out of CureVac (CVAC) in Q3 2023, closing a stake of 14,457 shares — an estimated $151K sold.

Fox Run Management first reported a position in CVAC in Q3 2022 and held it in 3 quarters. The position peaked at $248K in Q3 2022. 84 funds tracked by Wall St. Rank hold CVAC as of Q3 2023.

  • Fox Run Management reported no remaining CureVac position as of Q3 2023 after selling out during the quarter.
  • Fox Run Management sold 14,457 CureVac shares in Q3 2023, an estimated $151K.
  • Fox Run Management first reported a position in CureVac in Q3 2022 and held it in 3 quarters.
  • Fox Run Management's CureVac position peaked at $248K in Q3 2022.
  • 84 funds tracked by Wall St. Rank held CureVac as of Q3 2023.

Based on Fox Run Management's 13F filing for Q3 2023, filed 7 Nov 2023.